CNS Anticancer Drug Discovery and Development Conference White Paper

Victor A. Levin, Peter J. Tonge, James M. Gallo, Marc R. Birtwistle, Arvin C. Dar, Antonio Iavarone, Patrick J. Paddison, Timothy P. Heffron, William F. Elmquist, Jean E. Lachowicz, Ted W. Johnson, Forest M. White, Joohee Sul, Quentin R. Smith, Wang Shen, Jann N Sarkaria, Ramakrishna Samala, Patrick Y. Wen, Donald A. Berry, Russell C. Petter

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Following the first CNS Anticancer Drug Discovery and Development Conference, the speakers from the first 4 sessions and organizers of the conference created this White Paper hoping to stimulate more and better CNS anticancer drug discovery and development. The first part of the White Paper reviews, comments, and, in some cases, expands on the 4 session areas critical to new drug development: pharmacological challenges, recent drug approaches, drug targets and discovery, and clinical paths. Following this concise review of the science and clinical aspects of new CNS anticancer drug discovery and development, we discuss, under the rubric "Accelerating Drug Discovery and Development for Brain Tumors," further reasons why the pharmaceutical industry and academia have failed to develop new anticancer drugs for CNS malignancies and what it will take to change the current status quo and develop the drugs so desperately needed by our patients with malignant CNS tumors. While this White Paper is not a formal roadmap to that end, it should be an educational guide to clinicians and scientists to help move a stagnant field forward.

Original languageEnglish (US)
Pages (from-to)vi1-vi26
JournalNeuro-Oncology
Volume17
DOIs
StatePublished - May 24 2015

Fingerprint

Drug Discovery
Pharmaceutical Preparations
Critical Pathways
Drug Industry
Brain Neoplasms
Neoplasms
Pharmacology

Keywords

  • brain metastasis
  • chemotherapy
  • glioma
  • medulloblastoma
  • pharmacokinetics
  • pharmacology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Levin, V. A., Tonge, P. J., Gallo, J. M., Birtwistle, M. R., Dar, A. C., Iavarone, A., ... Petter, R. C. (2015). CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro-Oncology, 17, vi1-vi26. https://doi.org/10.1093/neuonc/nov169

CNS Anticancer Drug Discovery and Development Conference White Paper. / Levin, Victor A.; Tonge, Peter J.; Gallo, James M.; Birtwistle, Marc R.; Dar, Arvin C.; Iavarone, Antonio; Paddison, Patrick J.; Heffron, Timothy P.; Elmquist, William F.; Lachowicz, Jean E.; Johnson, Ted W.; White, Forest M.; Sul, Joohee; Smith, Quentin R.; Shen, Wang; Sarkaria, Jann N; Samala, Ramakrishna; Wen, Patrick Y.; Berry, Donald A.; Petter, Russell C.

In: Neuro-Oncology, Vol. 17, 24.05.2015, p. vi1-vi26.

Research output: Contribution to journalArticle

Levin, VA, Tonge, PJ, Gallo, JM, Birtwistle, MR, Dar, AC, Iavarone, A, Paddison, PJ, Heffron, TP, Elmquist, WF, Lachowicz, JE, Johnson, TW, White, FM, Sul, J, Smith, QR, Shen, W, Sarkaria, JN, Samala, R, Wen, PY, Berry, DA & Petter, RC 2015, 'CNS Anticancer Drug Discovery and Development Conference White Paper', Neuro-Oncology, vol. 17, pp. vi1-vi26. https://doi.org/10.1093/neuonc/nov169
Levin VA, Tonge PJ, Gallo JM, Birtwistle MR, Dar AC, Iavarone A et al. CNS Anticancer Drug Discovery and Development Conference White Paper. Neuro-Oncology. 2015 May 24;17:vi1-vi26. https://doi.org/10.1093/neuonc/nov169
Levin, Victor A. ; Tonge, Peter J. ; Gallo, James M. ; Birtwistle, Marc R. ; Dar, Arvin C. ; Iavarone, Antonio ; Paddison, Patrick J. ; Heffron, Timothy P. ; Elmquist, William F. ; Lachowicz, Jean E. ; Johnson, Ted W. ; White, Forest M. ; Sul, Joohee ; Smith, Quentin R. ; Shen, Wang ; Sarkaria, Jann N ; Samala, Ramakrishna ; Wen, Patrick Y. ; Berry, Donald A. ; Petter, Russell C. / CNS Anticancer Drug Discovery and Development Conference White Paper. In: Neuro-Oncology. 2015 ; Vol. 17. pp. vi1-vi26.
@article{a0554b836b0b4b6e929bdc9dc06da371,
title = "CNS Anticancer Drug Discovery and Development Conference White Paper",
abstract = "Following the first CNS Anticancer Drug Discovery and Development Conference, the speakers from the first 4 sessions and organizers of the conference created this White Paper hoping to stimulate more and better CNS anticancer drug discovery and development. The first part of the White Paper reviews, comments, and, in some cases, expands on the 4 session areas critical to new drug development: pharmacological challenges, recent drug approaches, drug targets and discovery, and clinical paths. Following this concise review of the science and clinical aspects of new CNS anticancer drug discovery and development, we discuss, under the rubric {"}Accelerating Drug Discovery and Development for Brain Tumors,{"} further reasons why the pharmaceutical industry and academia have failed to develop new anticancer drugs for CNS malignancies and what it will take to change the current status quo and develop the drugs so desperately needed by our patients with malignant CNS tumors. While this White Paper is not a formal roadmap to that end, it should be an educational guide to clinicians and scientists to help move a stagnant field forward.",
keywords = "brain metastasis, chemotherapy, glioma, medulloblastoma, pharmacokinetics, pharmacology",
author = "Levin, {Victor A.} and Tonge, {Peter J.} and Gallo, {James M.} and Birtwistle, {Marc R.} and Dar, {Arvin C.} and Antonio Iavarone and Paddison, {Patrick J.} and Heffron, {Timothy P.} and Elmquist, {William F.} and Lachowicz, {Jean E.} and Johnson, {Ted W.} and White, {Forest M.} and Joohee Sul and Smith, {Quentin R.} and Wang Shen and Sarkaria, {Jann N} and Ramakrishna Samala and Wen, {Patrick Y.} and Berry, {Donald A.} and Petter, {Russell C.}",
year = "2015",
month = "5",
day = "24",
doi = "10.1093/neuonc/nov169",
language = "English (US)",
volume = "17",
pages = "vi1--vi26",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - CNS Anticancer Drug Discovery and Development Conference White Paper

AU - Levin, Victor A.

AU - Tonge, Peter J.

AU - Gallo, James M.

AU - Birtwistle, Marc R.

AU - Dar, Arvin C.

AU - Iavarone, Antonio

AU - Paddison, Patrick J.

AU - Heffron, Timothy P.

AU - Elmquist, William F.

AU - Lachowicz, Jean E.

AU - Johnson, Ted W.

AU - White, Forest M.

AU - Sul, Joohee

AU - Smith, Quentin R.

AU - Shen, Wang

AU - Sarkaria, Jann N

AU - Samala, Ramakrishna

AU - Wen, Patrick Y.

AU - Berry, Donald A.

AU - Petter, Russell C.

PY - 2015/5/24

Y1 - 2015/5/24

N2 - Following the first CNS Anticancer Drug Discovery and Development Conference, the speakers from the first 4 sessions and organizers of the conference created this White Paper hoping to stimulate more and better CNS anticancer drug discovery and development. The first part of the White Paper reviews, comments, and, in some cases, expands on the 4 session areas critical to new drug development: pharmacological challenges, recent drug approaches, drug targets and discovery, and clinical paths. Following this concise review of the science and clinical aspects of new CNS anticancer drug discovery and development, we discuss, under the rubric "Accelerating Drug Discovery and Development for Brain Tumors," further reasons why the pharmaceutical industry and academia have failed to develop new anticancer drugs for CNS malignancies and what it will take to change the current status quo and develop the drugs so desperately needed by our patients with malignant CNS tumors. While this White Paper is not a formal roadmap to that end, it should be an educational guide to clinicians and scientists to help move a stagnant field forward.

AB - Following the first CNS Anticancer Drug Discovery and Development Conference, the speakers from the first 4 sessions and organizers of the conference created this White Paper hoping to stimulate more and better CNS anticancer drug discovery and development. The first part of the White Paper reviews, comments, and, in some cases, expands on the 4 session areas critical to new drug development: pharmacological challenges, recent drug approaches, drug targets and discovery, and clinical paths. Following this concise review of the science and clinical aspects of new CNS anticancer drug discovery and development, we discuss, under the rubric "Accelerating Drug Discovery and Development for Brain Tumors," further reasons why the pharmaceutical industry and academia have failed to develop new anticancer drugs for CNS malignancies and what it will take to change the current status quo and develop the drugs so desperately needed by our patients with malignant CNS tumors. While this White Paper is not a formal roadmap to that end, it should be an educational guide to clinicians and scientists to help move a stagnant field forward.

KW - brain metastasis

KW - chemotherapy

KW - glioma

KW - medulloblastoma

KW - pharmacokinetics

KW - pharmacology

UR - http://www.scopus.com/inward/record.url?scp=84946113022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946113022&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nov169

DO - 10.1093/neuonc/nov169

M3 - Article

C2 - 26403167

AN - SCOPUS:84946113022

VL - 17

SP - vi1-vi26

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

ER -